CytomX OKd on applications for antibody drug conjugates

  Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

- Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 -

https://www.biospace.com/article/releases/cytomx-therapeutics-announces-fda-clearance-of-ind-applications-for-cx-2051-a-probody-antibody-drug-conjugate-adc-targeting-epcam-and-cx-801-a-conditionally-activated-interferon-alpha-2b/